Read More

Bluebird Bio Details Plans For The Commercial Launch Of LYFGENIA Gene Therapy For Patients Ages 12 And Older With Sickle Cell Disease And A History Of Vaso-Occlusive Events; Bluebird Has Set Wholesale Acquisition Cost Of LYFGENIA In U.S. At $3.1M

Outcomes-based contract offerings available to both commercial payers and MedicaidLYFGENIA will be available through bluebird's established national network of Qualified Treatment Centers beginning in Q1 2024"my bluebird

BLUE